CAV1 and breast carcinoma: In our study, gene expression profiling of dasatinib-sensitive versus non-sensitive cells (in the absence of drug treatment) revealed significantly higher levels of CAV1 (Log2FC = 2.78, p-value = 1.2 × 10−9) and MSN (Log2FC = 2.71, p-value = 6.62 × 10−8) in dasatinib-sensitive breast cancer cell lines.